Also, CHK1 inhibitors, especially prexasertib, have been investigated, exhibiting limited efficacy as monotherapy in ES-SCLC [54], whilst combining CHK1 inhibitors with other agents like lurbinectedin or PARP inhibitors may enhance antitumor activity [55]. Here, CHEK1 is linked to small cell lung carcinoma.